Clorox (NYSE:CLX) PT Raised to $174.00

Clorox (NYSE:CLX) had its price objective upped by research analysts at JPMorgan Chase & Co. from $148.00 to $174.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 8.55% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Wells Fargo & Company cut their price target on Clorox from $135.00 to $130.00 and set an “underweight” rating on the stock in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft boosted their target price on Clorox from $144.00 to $151.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. BNP Paribas upgraded Clorox to a “strong sell” rating in a research note on Friday, September 6th. Barclays boosted their target price on Clorox from $122.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, DA Davidson restated a “neutral” rating and set a $153.00 target price on shares of Clorox in a research note on Friday, September 6th. Six research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Clorox currently has an average rating of “Hold” and a consensus price target of $150.36.

Clorox Trading Up 1.4 %

CLX opened at $160.30 on Friday. The stock’s fifty day moving average is $157.36 and its two-hundred day moving average is $144.78. The company has a market capitalization of $19.91 billion, a P/E ratio of 83.06, a PEG ratio of 3.19 and a beta of 0.41. Clorox has a 52 week low of $114.68 and a 52 week high of $169.09. The company has a quick ratio of 0.63, a current ratio of 1.03 and a debt-to-equity ratio of 5.04.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.28. Clorox had a return on equity of 281.12% and a net margin of 3.95%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. Analysts forecast that Clorox will post 6.64 earnings per share for the current year.

Insider Activity

In other news, EVP Angela C. Hilt sold 1,733 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the completion of the transaction, the executive vice president now owns 13,471 shares of the company’s stock, valued at $2,229,719.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.51% of the company’s stock.

Hedge Funds Weigh In On Clorox

Several institutional investors and hedge funds have recently modified their holdings of CLX. Vanguard Group Inc. raised its holdings in Clorox by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 15,277,580 shares of the company’s stock worth $2,339,150,000 after purchasing an additional 48,632 shares during the period. Nuance Investments LLC raised its holdings in Clorox by 150.6% in the 2nd quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock worth $218,035,000 after purchasing an additional 960,094 shares during the period. Van ECK Associates Corp raised its holdings in Clorox by 1,715.5% in the 2nd quarter. Van ECK Associates Corp now owns 1,461,207 shares of the company’s stock worth $199,411,000 after purchasing an additional 1,380,724 shares during the period. Bank of New York Mellon Corp raised its holdings in Clorox by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock worth $131,200,000 after purchasing an additional 120,716 shares during the period. Finally, Confluence Investment Management LLC acquired a new position in Clorox in the 1st quarter worth about $135,630,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.